Search

Jan 18, 2024
Addimmune's CEO on how the company is trying to harness modifying miRNAs to create a functional cure for HIV
Jeff Galvin explains how previous attempts at modifying CCR5 in T-cells have taught us to more precisely target HIV and from addition angles